WE DELIVER
Strategic intelligence
to reveal what’s shaping biopharma
Endpoints Signal taps the collective intelligence of the biopharma world to help leaders navigate an industry in flux. Signal turns in-depth survey data and market evidence into clear perspectives on science, capital and policy.
Latest Signal
Intelligence Report
Intelligence Report
Biopharma Sentiment Index (BPSI)
Q2 2026
The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric.
Latest Signal
Pulse Report
Pulse Report
Most Favored Nation Pulse Poll
MAY 2026
Just 7% of respondents think MFN-style policies will significantly lower US drug prices, while 53% expect policies to get watered down and have little impact.
Insights from our data
Read the full story
Biopharma Sentiment Index | Q2 2026Read the full story
Explore the shape of biopharma's mood
Put the full power of Signal to work for you
Endpoints Signal provides independent analysis and industry-wide perspective. Our proprietary benchmarks and data-driven reports help Endpoints subscribers spot emerging opportunities and manage risk before they surface.
Talk to us about custom insights from our data and the ability to reach our audience of biopharma leaders with questions of your own.
get in touch
